FDA Brief

Warning letters Drugs

FDA warning letter to

Vi-Jon, LLC

High riskIssued Mar 31, 2022Posted Apr 19, 2022Division of Pharmaceutical Quality Operations III

FDA cited Vi-Jon for manufacturing-rule violations after finding microbial water contamination, leaks, weak investigations, and data-integrity failures in OTC drugs and cosmetics.

What happened

FDA inspected the drug manufacturing facility in St. Louis, MO, from October 4 to October 13, 2021. Investigators found water-system sampling was not representative and Burkholderia cepacia, a waterborne bacterium, had been found repeatedly in finished drug products; they also saw undocumented water leaks, inadequate cleaning and maintenance, incomplete investigations of failing test results and complaints, and laboratory computer controls that allowed shared administrative access and deletion of files. FDA also cited insanitary conditions for cosmetics.

What FDA found

  1. FDA found the water-system sampling plan did not represent the whole system and did not adequately monitor or test for Burkholderia cepacia, a waterborne bacterium that had repeatedly contaminated finished drug products.

    21 CFR 211.160(b)
  2. FDA found inadequate cleaning and maintenance procedures, including undocumented water leaks, a leaking raw-material valve, and rust in a laboratory hood.

    21 CFR 211.67(b)
  3. FDA found failing test results and complaints were not thoroughly investigated, including Burkholderia cepacia contamination and missing or illegible lot codes.

    21 CFR 211.192
  4. FDA found laboratory computer controls were inadequate because quality-unit users shared an administrative account and files had been deleted, and computer audit trails were not reviewed before batch release.

    21 CFR 211.68(b)
  5. FDA found cosmetics were made under insanitary conditions, with stagnant water and leaking processing lines as potential sources of bacterial contamination.

    section 601(c) of the FD&C Act, 21 U.S.C. 361(c)
  6. FDA said executive management failed to provide proper oversight and that the quality system was ineffective.

    21 CFR parts 210 and 211

What FDA wants

FDA asks Vi-Jon to provide comprehensive corrective action plans, independent assessments, risk assessments, and remediation for the water system, investigations, data integrity, and quality-unit oversight, and strongly recommends a qualified CGMP consultant. The letter excerpt does not state a specific response deadline.

Who should pay attention

  • OTC drug and cosmetic brands that use contract manufacturers
  • companies buying hand sanitizers or personal-care products made at this site
  • quality teams responsible for water systems, complaints, and laboratory data integrity

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. CNC Noodle Corporation

    FDA warned CNC Noodle Corporation that its Hayward, California noodle plant had insanitary conditions, no pathogen or allergen controls, and mislabeled products.

    High risk
  2. USV Private Limited

    FDA warned USV Private Limited that its sterile injectable manufacturing in Daman, India, had aseptic-processing, facility-design and visible-particulate violations.

    High risk
  3. Next Medical Products Company, LLC

    FDA warns Next Medical Products that its ultrasound gels were contaminated and made without required quality controls or clearance.

    High risk
  4. Northland Nuclear Medicine, LLC

    FDA warned Northland Nuclear Medicine in Bismarck, ND, that its PET drugs are adulterated because it failed to investigate microbial contamination and low yields.

    High risk